Cellular Dynamics International (NASDAQ: ICEL) and Mesoblast Limited (NASDAQ:MESO) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for Cellular Dynamics International and Mesoblast Limited, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellular Dynamics International 0 0 0 0 N/A
Mesoblast Limited 0 2 4 0 2.67

Mesoblast Limited has a consensus target price of $14.25, suggesting a potential upside of 101.27%. Given Mesoblast Limited’s higher possible upside, analysts plainly believe Mesoblast Limited is more favorable than Cellular Dynamics International.

Valuation and Earnings

This table compares Cellular Dynamics International and Mesoblast Limited’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Cellular Dynamics International N/A N/A N/A N/A N/A
Mesoblast Limited $2.41 million 249.55 -$86.99 million ($0.96) -7.38

Cellular Dynamics International has higher revenue, but lower earnings than Mesoblast Limited.

Institutional and Insider Ownership

3.0% of Mesoblast Limited shares are owned by institutional investors. 18.8% of Mesoblast Limited shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


This table compares Cellular Dynamics International and Mesoblast Limited’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellular Dynamics International -88.12% -57.59% -38.09%
Mesoblast Limited -3,184.70% -14.79% -11.55%


Mesoblast Limited beats Cellular Dynamics International on 7 of the 8 factors compared between the two stocks.

Cellular Dynamics International Company Profile

Cellular Dynamics International, Inc. develops and produces functioning human cells in industrial quantities. The Company’s products include true human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs) and custom iPSCs and iCell products (MyCell products). It markets its products for use in life science in vitro research and development, as well as applied product testing, stem cell banking and in vivo cellular therapeutics. It is also in the process of developing human cells as cellular therapeutics. The market for in vitro drug discovery, toxicity testing and applied testing, including chemical safety, has employed models, such as primary cells, transformed (immortalized) cells and live animals that act as surrogates for functioning human cells. Its iCell and MyCell products consist of iCell Cardiomyocytes, iCell Neurons, iCell DopaNeurons, iCell Endothelial Cells, iCell Hepatocytes, MyCell and Media and reprogramming kit.

Mesoblast Limited Company Profile

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Receive News & Ratings for Cellular Dynamics International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Dynamics International Inc and related companies with MarketBeat.com's FREE daily email newsletter.